RIA1 (C-5) inhibitors belong to a specific chemical class of compounds that have demonstrated the ability to inhibit the activity of RIA1 (also known as Elongator complex protein 5). RIA1 is a component of the Elongator complex, which is involved in various cellular processes, including tRNA modification and transcription elongation. The inhibitors targeting RIA1 (C-5) are designed to specifically interact with the protein, disrupting its normal function. Chemically, RIA1 (C-5) inhibitors exhibit a distinct molecular structure that allows them to interact with the active site or binding pocket of RIA1. These compounds typically possess specific functional groups or motifs that facilitate the formation of stable interactions with the target protein, thereby preventing its normal enzymatic or regulatory activities.
The development of RIA1 (C-5) inhibitors involves a rigorous process of structure-activity relationship studies and medicinal chemistry optimization. Researchers employ a combination of computational modeling, high-throughput screening, and chemical synthesis to identify and refine lead compounds that possess favorable pharmacokinetic and pharmacodynamic properties. The goal is to produce potent and selective inhibitors that specifically target RIA1 without significantly affecting other cellular components or processes. Once identified, RIA1 (C-5) inhibitors can be further characterized through in vitro and in vivo studies. These investigations evaluate their potency, selectivity, and mechanism of action. In addition, researchers explore their cellular effects and assess their impact on relevant cellular pathways and processes influenced by RIA1. These studies provide valuable insights into the potential biological implications of inhibiting RIA1 (C-5). Overall, RIA1 (C-5) inhibitors represent a chemical class of compounds designed to selectively and potently inhibit the activity of RIA1, a component of the Elongator complex. Their specific chemical structures and interactions with the target protein allow them to modulate RIA1 function, providing researchers with valuable tools to investigate the biological roles of RIA1 and its potential involvement in various cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib is a kinase inhibitor that has been shown to have inhibitory effects on EFL1 activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is another kinase inhibitor that has been reported to inhibit EFLLike Ribociclib, it is primarily studied in the research of breast cancer. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) that has also demonstrated inhibitory effects on EFLIt is used in the research of certain types of breast cancer. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $143.00 $260.00 | 1 | |
Linsitinib is an inhibitor of insulin-like growth factor receptor (IGF-1R) signaling, and it has been shown to inhibit EFL1 activity. It has been investigated for its potential in cancer therapy. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a phosphoinositide 3-kinase (PI3K) inhibitor that has been reported to inhibit EFLIt has been studied in research models for various types of cancer. | ||||||
AZD1208 | 1204144-28-4 | sc-503188 | 10 mg | $316.00 | 1 | |
AZD1208 is an inhibitor of the serine/threonine kinase PIM1, and it has been found to inhibit EFL1 activity. It has been investigated for its potential in hematological malignancies. | ||||||
LY2606368 | 1234015-52-1 | sc-507521 sc-507521A sc-507521B sc-507521C sc-507521D sc-507521E | 5 mg 10 mg 25 mg 100 mg 1 g 10 g | $176.00 $300.00 $500.00 $1900.00 $8000.00 $25000.00 | ||
LY2606368 is a Chk1 inhibitor that has been shown to inhibit EFLIt has been evaluated in research studies for its anticancer activity. | ||||||
PF-3758309 | 898044-15-0 | sc-478493 | 10 mg | $260.00 | ||
PF-3758309 is a dual inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2). It has been reported to inhibit EFL1 activity and has been investigated in cancer models. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
CHIR-99021 is a selective inhibitor of glycogen synthase kinase 3 (GSK-3). | ||||||
TAK-733 | 1035555-63-5 | sc-364630 sc-364630A | 5 mg 10 mg | $340.00 $640.00 | 1 | |
TAK-733 is a small-molecule inhibitor of the mitogen-activated protein kinase kinase (MEK) pathway. It has been reported to inhibit EFL1 and has been evaluated for its anticancer effects. | ||||||